INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed human malignancies worldwide, with approximately 841,080 new cases in 2018. Accumulated genetic mutations and epigenetic alterations induced by risk factors such as reactive oxygen species, inflammatory factors and fibrosis are related to the incidence and progression of HCC.2,3 Although great developments in diagnosis and therapeutic strategies have occurred in recent years, such as hepatic resection, liver transplantation, transcatheter arterial...
chemoembolization (TACE) and multikinase inhibitor sorafenib, the long-term survival rates of HCC remain dismal due to compensatory revascularization and drug resistance.\(^5,^6\) Therefore, it is necessary to explore the underlying mechanism of HCC pathogenesis to uncover new therapeutic strategies against HCC.

Tetraspanins are a group of cell surface-associated membrane proteins expressed in a wide variety of cell types, and they are characterized by four transmembrane domains.\(^6,^7\) It is well established that tetraspanin proteins mediate cellular signal transduction and play important roles in the regulation of many physiological properties including cell motility, adhesion, proliferation, invasion and differentiation,\(^8\) and some tetraspanin molecules have been associated with progression of various human malignancies, such as melanoma, non-small cell lung cancer (NSCLC), breast cancer and pancreatic cancer.\(^9,^10\) For example, tetraspanin CD82 is frequently down-regulated in advanced stages of cancer, and overexpression of CD82 inhibits tumour migration and invasion via regulation of several signal pathways such as hepatocyte growth factor receptor (HGFR) pathway.\(^11,^12\) Tetraspanin CD9 has been reported to inhibit the proliferation and tumorigenicity of colon carcinoma cells,\(^13\) and ectopic expression of CD9 in NSCLC suppresses cell motility and promotes apoptotic cell death by regulating AKT phosphorylation and MMP2 secretion.\(^14\)

The cluster of differentiation 63 (CD63), also known as melanoma-associated antigen ME491 or MLA1, is the first identified member of the tetraspanin family.\(^15\) CD63 is ubiquitously expressed and mainly localized within the endosomal system and at the cell surface.\(^16\) Previous studies have implicated a role of CD63 in cellular transport of other proteins.\(^16-18\) For instance, it has been found in the complex with MHC II, which suggested that CD63 might chaperone MHCII molecules through the endosomal system and plays a role in antigen presentation via MHC II.\(^19\) More importantly, emerging evidences have implicated a correlation between abnormal CD63 expression and tumour progression. Although CD63 was first identified to be expressed in early-stage melanoma cells, it is reduced while tumour cells become more invasive, implying a negative role of CD63 in tumour invasiveness.\(^20\) In other tumours including lung cancer and breast cancer, low CD63 expression is correlated with poor prognosis of patients.\(^21\) These findings suggested that CD63 is related to tumour cell motility and metastasis. However, its expression and functions in HCC remain to be elucidated.

In the present study, we resorted to investigate the role of CD63 in the development of HCC and explore the underlying molecular mechanisms using molecular and cell biology experiments in vitro and in vivo.

## 2 | MATERIAL AND METHODS

### 2.1 | Patients and HCC tissue samples

Primary human HCC tissues and paired adjacent normal tissues were collected from 35 patients at Shanghai East Hospital, Tongji University School of Medicine, China. All the specimens were snap-frozen in liquid nitrogen immediately after resection for future use. Informed consent was obtained from each patient, and the use of the samples for the present study has been approved by the ethics committee of Shanghai East Hospital, Tongji University School of Medicine, China.

### 2.2 | Tissue microarray (TMA) and immunohistochemistry

For immunohistochemistry analysis, a TMA containing 75 paired human HCC tissues and adjacent normal tissues was purchased from Shanghai Outdo Biotech (LVH150C053). The clinicopathological information of the patients can be checked at the website: http://www.superchip.com.cn/biology/tissue.html. Human antibody against CD63 (#sc-15363, Santa Cruz Biotechnology, USA) was used to perform immunohistochemistry analysis according to the standard protocol of manufacturer (Outdo Biotech, Shanghai, China), respectively. The staining results were analysed by two pathologists blinded to the clinical information as described previously.\(^22\)

### 2.3 | Cell culture and reagents

Human HCC cell lines Huh7, L02, MHCC-LM3 and PLC/PRF/5 were purchased from the Shanghai Cell Bank of the Chinese Academy Sciences, Shanghai, China. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Corning, Inc) supplemented with 10% foetal bovine serum (FBS, Corning, Inc) and 1% penicillin/streptomycin (M&C Gene Technology Ltd.) and incubated at 37 °C with 5% CO\(_2\). STAT3-specific inhibitor BP-1-102 was purchased from Selleckchem, Houston, TX, USA.

### 2.4 | DNA isolation and quantitative real-time polymerase chain reaction (qPCR) analysis

Total RNAs were extracted with TRIzol reagents from Sigma-Aldrich, Merck KGaA, Germany according to the protocol of manufacturer and reverse transcribed into cDNA using the PrimeScript™ RT Reagent kit with gDNA Eraser (Takara) and stored at −20°C before use. Standard qPCR analysis was performed with SYBR-Green reagents (Takara) on an ABI QuantStudio™ 6 Flex system according to the specifications of manufacturers. \(2\Delta\Delta\text{Ct}\) method was used to calculate relative mRNA levels of target genes, and β-actin was used endogenous control. The following primer sequences were used: CD63 forward: 5'-TTGGAAGGAAATGAAATGTG-3', reverse: 5'-TCTTTCCTCCATACAGCCTTCTT-3'; IL-6 forward: 5'-ACAACCCTGACCCCAACCACAAAT-3', reverse: 5'-AGCTGGCGCAGAATGAGA TGAAGT-3'; IL-27 forward: 5'-ACCGCTTTGCGGAATCTCA-3', reverse: 5'-AGGTACGGGAACATCAGGGA-3'; β-actin forward: 5'-CC TGGCACCAGCAATG-3', reverse: 5'-GGGCGGACTCGTCATACT-3'.
2.5 | Cell transfection

For CD63 overexpression, pEnter-CD63 plasmid (GeneBank Accession Number: NM_001780) was purchased from Vigeone Biosciences, Shandong, China. Specific small interference RNA against CD63 (siCD63) and non-specific control (siNC) were purchased from Shanghai Genepharma Company. The sequences were as follows: siCD63 sense 5′-GUGGGAUUAAUUUCAACGA-3′; siNC sense 5′-UUCUCCGAACGUUCACGUdTdT-3′. Transfection of siRNAs or plasmids was carried out using Lipofectamine 3000 Reagents (Introgen) according to the protocol of manufacturer. To establish stably infected cell lines with CD63 overexpression or knockdown, RNA interference lentivirus (sequence of siCD63 was used) and CD63 overexpression lentivirus were purchased from GenePharma, Shanghai China. Cells were infected with the indicated lentiviruses with the assistance of polybrene (4 μg/mL), and stably infected cells were selected with puromycin (2.5 μg/mL).

2.6 | Western blot analysis

Total proteins were isolated from HCC cells with RIPA Lysis Buffer (Beyotime, Jiangsu, China). After centrifugation at the speed of 14000 g for 10 minutes at 4°C, cell lysates were resolved by 5% SDS loading buffer and boiled for 5 minutes. Equal amounts of cell lysates were electrophoresed on 10% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories). After blocking in 5% non-fat dry milk supplemented with 0.1% Tween-20 in PBS (PBST) at room temperature for 1 hour, the membrane was incubated with specific primary antibodies overnight at 4°C followed by incubation with corresponding secondary antibodies for 1 hour. The immunoreactive signal was visualized using the Odyssey Infrared imaging system (LI-COR Biosciences). The antibodies used in the present study included: anti-CD63 (1:200, #sc-15363, Santa Cruz Biotechnology, USA), anti-STAT3 (1:2000, #9139, Cell Signaling Technology),...
anti-pSTAT3 (Y705, 1:500, #9145, Cell Signaling Technology) and anti-β-actin (1:1,000, #81178, Santa Cruz Biotechnology).

2.7 | Dual-luciferase reporter assay

Briefly, HCC cells were seeded into a 24-well plate and incubated for 24 hours before transfection, then 250 ng of STAT3 reporter plasmid (Genomeditech) and 10 ng of SV40, a Renilla luciferase expression plasmid as an internal control were cotransfected into the prepared cells. 24 hours after transfection, cells were harvested and dual-luciferase reporter assay was carried out with a Dual-Glo Luciferase kit according to the manufacturer’s specifications (Promega). A GloMax® 96 Microplate Luminometer (Promega) was used to quantify both firefly and Renilla luciferase activities. All experiments were done in triplicate and repeated at least 3 times.

2.8 | RNA-sequencing and bioinformatics analysis

Briefly, Huh7 cells were seeded into a 10-cm dish at a confluence of 80% and incubated for 24 hours, after which total RNA was extracted with TRIzol reagents (Sigma-Aldrich, Merck KGaA) according to the protocol of manufacturer and immediately snap-frozen in liquid nitrogen before RNA-sequencing. The RNA-sequencing was performed on a BGISEQ-500 platform and mapped by BGI. The log2 ratio of fragments per kilobase of transcript per million (FPKM) between Huh7-VEC and Huh7-CD63 cells was calculated and genes with an absolute value of log2 FPKM ≥ 1 or ≤−1 and an adjusted P value (q value) < .05 were considered to be differentially expressed genes. Volcano plot exhibiting differentially expressed genes were made using ggplot2 package in R language. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Set Enrichment Analysis (GSEA) were performed to analyse the pathways which the down-regulated genes in Huh7-CD63 cells were enriched in.

2.9 | CCK-8 cell proliferation assay

Cell Counting Kit-8 reagent (CCK-8, Dojindo Laboratories) was used to perform cell proliferation assays. Briefly, the indicated cells were seeded into 96-well plates in triplicate (3000 cells/well) after transfection. At scheduled time points (0, 24, 48, 72 and 96 hours), 10 μL of CCK-8 was added into each well and incubated for 1 hour at 37°C. An automated plate reader (SpectraMax M5, Molecular Devices, LLC) was used to read the absorbance at a wavelength of 450 nm. Each experiment was performed in triplicate and repeated 3 times independently.

2.10 | Colony formation assay

For colony formation assays, stably infected HCC cells were cultured in a 6-well plate at a density of 1000 cells per well and incubated at 37°C for 1-2 weeks; then, the colonies were harvested. After fixation in 4% paraformaldehyde, the colonies were stained with crystal violet (Sangon Biotech) for 10 minutes. Images of the colonies were captured, and the number of cells was counted using Image J software.

2.11 | Cell migration assay

Cell migration assays were performed with a 24-well transwell chamber (pore size, 8 μm; Costar). Briefly, 30 000 HCC cells suspended in 400 μL DMEM without FBS were added into the upper chamber, while 800 μL of DMEM containing 10% FBS was added into the bottom chamber. After incubating at 37°C for 48 hours, the migrated cells were harvested and stained with crystal violet (Sangon Biotech) for 20 minutes. A phase-contrast microscope (Leica DM6000B, Leica Microsystems) was used to photograph and count the number of migrated cells in five randomly selected fields at a magnification of ×100.

2.12 | Animal experiments

To establish a xenograft model of HCC, 4- to 6-week-old male BALB/c nude mice were purchased from Sippr-BK laboratory animal corporation, Shanghai, China. Equal amount of stably infected HCC cells (2 × 10^6 cells) were injected subcutaneously into each flank of armpit area of nude mice, respectively (n = 5). After 4 weeks, the mice were euthanized,

| Table 1: The correlation of CD63 expression with clinicopathological features of HCC |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Case number     | Weak staining   | Strong staining | P value         |
| Age (y)         |                 |                 |                 |
| >60             | 18              | 10              | 8               | .931            |
| ≤60             | 57              | 31              | 26              |                 |
| Gender          |                 |                 |                 |
| Male            | 62              | 33              | 29              | .584            |
| Female          | 13              | 8               | 5               |                 |
| Liver cirrhosis |                 |                 |                 |
| No              | 27              | 15              | 12              | .908            |
| Yes             | 48              | 26              | 22              |                 |
| Tumour size     |                 |                 |                 |
| <5 cm           | 36              | 14              | 22              | .008*           |
| ≥5 cm           | 39              | 27              | 12              |                 |
| Metastasis      |                 |                 |                 |
| M0              | 71              | 37              | 34              | .009*           |
| M1              | 4               | 4               | 0               |                 |
| AJCC stage      |                 |                 |                 |
| I, II           | 45              | 18              | 27              | .002*           |
| III, IV         | 30              | 23              | 7               |                 |
| Total           | 75              | 41              | 34              |                 |

* P < .05 was considered as a significant association among the variables.
and each tumour was resected and weighted after 4 wk. $^*P < .05$, $^{**}P < .01$

and each tumour was resected and weighted after resection. The animal handling and experimental procedures were abided by the Ethics Committee of Shanghai East Hospital, Tongji University School of Medicine.

2.13 | Enzyme-linked immunosorbent assay (ELISA)

To evaluate the effects of CD63 on IL-6 and IL-27 protein levels, the indicated HCC cells were treated with LPS (1 μg/mL, Beyotime) for 6 hours to induce the production of inflammatory cytokines and the culture supernatants were collected. IL-6 and IL-27 protein levels were measured using ELISA kits (#KE00007 and #KE00089, Proteintech) according to the manufacturer’s instructions.

2.14 | Statistical analysis

Quantitative data were represented as the means ± SD, and GraphPad Prism software 7.0 was used to perform statistical analyses. The chi-square test was used to explore the relationships between CD63 expression and clinicopathological parameters of HCC patients. Statistical significance was determined by one-way analysis of variance (one-way ANOVA), and Dunnett’s multiple comparison test was used as a post hoc test or the Student t test. A $P$ value less than 0.05 was considered as statistically significant. $^*P < .05$, $^{**}P < .01$.

3 | RESULTS

3.1 | CD63 expression is reduced in HCC tissues and associated with clinicopathological parameters of HCC patients

The protein expression of CD63 in a tissue microarray (TMA) consisting of 75 HCC tumour tissues and paired adjacent normal tissues was analysed by immunohistochemistry. The results showed that CD63 was frequently down-regulated in tumour tissues compared with adjacent
normal tissues at protein level (Figure 1A,B). Next, we analysed the relationship between CD63 expression and clinicopathological parameters in the TMA. Lower CD63 expression was significantly associated with larger tumour size ($P < 0.05$), distant site metastasis ($P < 0.01$) and higher TNM stage ($P < 0.01$) (Table 1 and Figure 1C). Furthermore, the mRNA level of CD63 in additional 35 paired HCC tissues was determined by qPCR analysis. Consistently, CD63 mRNA expression in tumour tissues was remarkably lower than in adjacent normal tissues (Figure 1D), and it exhibited a $<0.5$-fold decrease in 21/35 (60%) paired tissues (Figure 1E). Taken together, these results suggested that CD63 expression is reduced in HCC tissues and directly associated with the development of HCC.

3.2 | CD63 inhibits HCC cell proliferation in vitro and tumorigenicity in animal models

To explore the impacts of CD63 on cell proliferation of HCC, we intervened its expression by transfecting CD63-expressing plasmids (pCD63) or siRNAs targeting CD63 (siCD63) into HCC cell lines, respectively. Western blot results confirmed the efficiencies of pCD63 and siCD63 (Figure 2A). As the same time, CCK-8 assays were employed to detect cell proliferation. As shown in Figure 2B, HCC cells transfected with pCD63 exhibited a significantly lower growth rate comparing with the control group, whereas knockdown of CD63 by siCD63 resulted in opposite results. Furthermore, CD63 expression was stably overexpressed or silenced by transducing the HCC cells with lentiviruses (LV-CD63 or LV-shCD63, Figure 2C), and colony formation assays were conducted. In line with the results of CCK-8 assays, colonies formed from cells with increased CD63 expression were significantly less and smaller than those from the control cells, while blockade of CD63 attenuated colony formation capacity of HCC cells (Figure 2D). In addition, a xenograft mice model was established to validate these findings in vivo. As expected, CD63 overexpression significantly inhibited tumour growth of Huh7 cells, while knockdown of CD63 promoted tumorigenicity of MHCC-LM3 cells (Figure 2E). Therefore, these results demonstrated that CD63 plays a critical role in suppressing HCC cell proliferation in vitro and in vivo.

3.3 | CD63 negatively regulates HCC cell migration in vitro

In previous studies, CD63 has been associated with tumour metastasis in other tumours including melanoma and breast cancer. Therefore, we next examined whether CD63 could influence HCC cell migration ability in vitro. After intervening CD63 expression in the indicated HCC cell lines, transwell migration assays were performed. As presented in Figure 3A,B, overexpression of CD63 significantly reduced the migratory cell number of Huh7 and L02 cells. In contrast, CD63 silencing strongly promoted cell migration ability of MHCC-LM3 and PLC/PRF/5 cells. Thus, our results suggested a negative role of CD63 in HCC cell migration.

3.4 | CD63 inhibits inflammation-related oncogenic signalling pathways in HCC cells

To explore the molecular mechanisms through which CD63 inhibited HCC cell proliferation and migration, RNA-sequencing was applied using Huh7 cells with ectopic CD63 expression, and global
A. Downregulated genes (blue) and upregulated genes (red) are shown on a scatter plot of -log10(p-value) vs. log2(fold change).

B. Pathway enrichment analysis showing significant pathways in cancer-related processes.

C. Enrichment score for various pathways:
   - IL-17 signaling pathway
   - Cytokine-cytokine receptor interaction
   - NOD-like receptor signaling pathway
   - TNF signaling pathway

D. Heatmap showing gene expression levels across different conditions.

E. Relative mRNA expression fold change for IL-6 and IL-27.
   - LV-VEC: Control
   - LV-shCD63: Knockdown
   - LV-shVEC: Vector control
transcriptional expression profile differences were analysed. Volcano plot showed that 393 genes were up-regulated and 539 genes were down-regulated in cells with CD63 overexpression when compared with control cells (Figure 4A). Furthermore, the down-regulated genes were used to perform KEGG pathway analysis. The results showed that the down-regulated genes were highly enriched in inflammation-related oncogenic signalling pathways, such as IL-17 signalling pathway, NF-kB signalling pathway and NOD-like receptor signalling pathway (Figure 4B). Besides, the gene set enrichment analysis (GSEA) was used to verify these results. Compared to the control group, increased CD63 expression significantly inhibited the transcriptional activity of STAT3 in L02 cells, while knockdown of CD63 remarkably increased the transcriptional activity of STAT3 in MHCC-LM3 cells (Figure 5B). These mechanistic studies demonstrated that CD63 could inactivate STAT3 in HCC cells.

3.5 | CD63 has a negative impact on STAT3 activation in HCC

Considering that both IL-6 and IL-27 contribute to tumour progression through JAK/STAT3 signalling pathway, we next elucidated whether CD63 regulated the activation of signal transducer and activator of transcription-3 (STAT3) by Western blot analysis. As shown in Figure 5A, overexpression of CD63 significantly decreased the level of phosphorylated STAT3 (Y705), while total protein levels of STAT3 showed no obvious difference. In contrast, silencing CD63 expression led to opposite results. To verify this regulation of STAT3 by CD63, a dual-luciferase reporter assay was performed using STAT3 response element reporter plasmid. As expected, overexpression of CD63 inhibited the transcriptional activity of STAT3 in L02 cells, while knockdown of CD63 remarkably increased the transcriptional activity of STAT3 in MHCC-LM3 cells (Figure 5B). These mechanistic studies demonstrated that CD63 could inactivate inflammation-related oncogenic signalling pathways.

3.6 | STAT3 inhibition blocks CD63 knockdown-induced cell growth and migration

To assess the effects of the relationship between CD63 and STAT3 on cell growth and migration in HCC, a STAT3-specific inhibitor
BP-1-102 was used to block STAT3 activation\(^\text{27}\) (Figure 6A). Results of CCK-8 and colony formation assays showed that treatment with BP-1-102 significantly abolished CD63 knockdown-induced cell growth and colony formation of MHCC-LM3 cells (Figure 6B, C). Similarly, the data from transwell migration assays also demonstrated that BP-1-102 treatment dramatically attenuated the migratory ability of CD63 silenced MHCC-LM3 cells (Figure 6D). These findings collectively hinted us that STAT3 signalling is required for the negative effects of CD63 on cell proliferation and migration in HCC.

## DISCUSSION

Although previous studies have improved early diagnosis and treatment of HCC, the underlying mechanisms of initiation and development are largely unknown, which are critical for the development of effective interventions against HCC. In the present study, we demonstrated for the first time that tetraspanin CD63 is a potential tumour suppressor in HCC. Our clinical investigation showed that CD63 expression was frequently down-regulated in HCC tissues, and reduced CD63 expression was associated with larger tumour size, distant site metastasis and higher TNM stages.

CD63 is an important member of the tetraspanin superfamily involved in the regulation of a variety of cellular physiological activities such as membrane protein trafficking, cell fusion, adhesion, motility and cell differentiation, and abnormal CD63 expression has been associated with different human malignancies. Consistent with some previous reports\(^\text{20,21,28}\), our findings revealed that CD63 inhibits HCC cell proliferation and migration in vitro, and results of animal experiments confirmed its negative role in tumour growth in vivo. Further RNA-sequencing and bioinformatics analysis suggested that overexpression of CD63 in HCC cells significantly inhibited the activities of inflammation-related oncogenic signalling pathways including IL-17 signalling pathway, NF-κB signalling pathway and NOD-like receptor signalling pathway, which are known to stimulate inflammation and inhibit immunoreaction in tumour microenvironments, thus promoting initiation and progression of various tumours\(^\text{29-31}\).

Importantly, we identified that cytokines IL-6 and IL-27 are down-stream targets of CD63, as evidenced by the results of RNA-seq and qPCR analysis that overexpression of CD63 significantly inhibited IL-6 and IL-27 expression in HCC cells. Elevated levels of IL-6 and IL-27 have been observed in chronic inflammatory conditions, such as rheumatoid arthritis and a lot of hematopoietic malignancies and solid tumours.\(^\text{32,33}\) In the pathogenesis of cancer, elevated IL-6 and IL-27 could stimulate the activation of JAK1 and JAK2 enzymes, which subsequently mediate tyrosine phosphorylation of STAT3 at Tyr705. After translocation into nucleus, activated STAT3 regulates transcription of its target genes encoding regulators of cellular proliferation and survival, such as cyclin D1 and survivin.\(^\text{24,34}\) Thus, targeting hyperactivated IL-6/IL-27-JAK-STAT3 pathway is beneficial in the treatment of certain cancers. Our results demonstrated that CD63 inhibited STAT3 activation possibly through inhibiting IL-6 and IL-27 expression. Further cell biology experiments confirmed that CD63 may exert its function via inhibiting STAT3 activity.
of osteosarcoma also reported that knockdown of CD63 resulted in decreased pY705-STAT3 expression,\textsuperscript{25} which supports our findings in HCC. Therefore, these data establish a CD63-IL-6/IL-27-STAT3 axis involved in the regulation of HCC cell proliferation and migration. However, it is still unknown how CD63 regulates IL-6 and IL-27 expression in HCC cells.

It is well established that CD63 is an important biomarker of exosomes, which are microvesicles secreted by most types of cells and participate in intercellular communication via transmitting its cargo including proteins and nucleic acids into receptor cells.\textsuperscript{36,37} Intriguingly, Cheng et al reported that a specific type of exosomes (p120ctn) inhibited HCC cell progression via STAT3 pathway, hinting us that CD63 possibly regulates inflammation-related oncogenic pathways by influencing biogenesis and secretion of exosomes.\textsuperscript{38} However, more studies need to be done in order to verify this hypothesis.

In conclusion, these clinical and mechanistic findings identified a novel CD63-IL-6/IL-27-STAT3 axis in HCC tumorigenesis and development, and targeting this axis is a potential therapeutic strategy against HCC.

ACKNOWLEDGEMENTS
This study was partially supported by grants from the National Natural Science Foundation of China (No. 81772567 and 81972290), Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (No.PWZxq2017-13) and the Outstanding Clinical Discipline Project of Shanghai Pudong (No. PWYgy2018-02).

CONFLICT OF INTEREST
The authors declare there is no conflict of interest.

AUTHOR CONTRIBUTION
Shijun Yu: Data curation (equal); Investigation (equal); Methodology (equal); Writing-original draft (lead). Jingde Chen: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal). Ming Quan: Conceptualization (equal); Data curation (equal); Formal analysis (equal). Li Li: Data curation (equal); Formal analysis (equal); Funding acquisition (equal). Yandong Li: Investigation (equal); Project administration (equal); Supervision (equal); Validation (equal). Yong Gao: Investigation (equal); Project administration (equal); Supervision (equal); Writing-review & editing (equal).

ETHICAL APPROVAL
This study has been approved by the ethics committee of Shanghai East Hospital, Tongji University School of Medicine, China.

DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are available from the corresponding author upon request.

ORCID
Yandong Li \textsuperscript{D} https://orcid.org/0000-0002-0233-3031

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. Allison MR, Lovell MJ. Liver cancer: the role of stem cells. Cell Prolif. 2005;38(6):407-421.
3. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108(8):1314-1321.
4. Brux J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844-855.
5. Worns MA, Gallie PR. Hepatocellular carcinoma in 2017: Two large steps forward, one small step back. Nat Rev Gastroenterol Hepatol. 2018;15(2):74-76.
6. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397-422.
7. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6(10):801-811.
8. Yunta M, Lazo PA. Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal. 2003;15(6):559-564.
9. Boucheix C, Duc GH, Jasmin C, Rubinstein E. Tetraspanins and malignancy. Expert Rev Mol Med. 2001;1:1-17.
10. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9(1):40-55.
11. Tonoli H, Barrett JC. CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med. 2005;11(12):563-570.
12. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 2006;240(2):183-194.
13. Ovalle S, Gutierrez-Lopez MD, Olmo N, et al. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer. 2007;121(10):2140-2152.
14. Saito Y, Tachibana I, Takeda Y, et al. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer. 2006;66(19):9557-9565.
15. Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Can Res. 1988;48(11):2955-2962.
16. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res. 2009;315(9):1584-1592.
17. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, Boucheix C. CD9, CD63, CD81, and CD2 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol. 1996;26(11):2657-2665.
18. Flannery AR, Czibener C, Andrews NW. Mammary carcinoma cells exhibit a tetraspanin expression pattern associated with tumor progression. Oncol Rep. 2006;19:357-362.
19. Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F. The role of tetraspanin CD63 in antigen presentation via MHC class II. J Immunol. 2003;169(1):397-408.
20. Jang HI, Lee H. A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med. 2003;35(4):317-323.
21. Kwon MS, Shin SH, Yim SH, et al. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer. 2007;57(1):46-53.
22. Yu S, Wang X, Dou N, Zhou J, Gao Y, Li Y. B-cell lymphoma-2-associated transcription factor 1 is overexpressed and contributes to sorafenib resistance in hepatocellular carcinoma. Hepatol Res. 2019;49(11):1329-1340.
23. Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeilinger R, Deissler H. Expression of tetraspanin adaptor proteins below defined threshold values is associated with intra invasiveness of mammary carcinoma cells. Oncol Rep. 2003;10(2):405-410.
24. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol*. 2018;15(4):234-248.

25. Fu H, Tang YY, Ouyang XP, et al. Interleukin-27 inhibits foam cell formation by promoting macrophage ABCA1 expression through JAK2/STAT3 pathway. *Biochem Biophys Res Comm*. 2014;452(4):881-887.

26. Hirahara K, Onodera A, Villarino AV, et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. *Immunity*. 2015;42(5):877-889.

27. Zhang X, Yue P, Page BD, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. *Proc Natl Acad Sci USA*. 2012;109(24):9623-9628.

28. Liu WH, Li X, Zhu XL, Hou ML, Zhao W. CD63 inhibits the cell migration and invasion ability of tongue squamous cell carcinoma. *Oncol Lett*. 2018;15(6):9033-9042.

29. Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. *Trends Mol Med*. 2016;22(3):230-241.

30. Mitchell JP, Carmody RJ. NF-kappaB and the transcriptional control of inflammation. *Int Rev Cell Mol Biol*. 2018;335:41-84.

31. Liu P, Lu Z, Liu L, et al. NOD-like receptor signaling in inflammation-associated cancers: from functions to targeted therapies. *Phytochemistry*. 2019;64:152925.

32. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. *Semin Immunol*. 2014;26(1):54-74.

33. Duan Y, Jia Y, Wang T, Wang Y, Han X, Liu L. Potent therapeutic target of inflammation, virus and tumor: focus on interleukin-27. *Int Immunopharmacol*. 2015;26(1):139-146.

34. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. *J Clin Oncol*. 2009;27(26):4422-4432.

35. Ando T, Kudo Y, Iizuka S, et al. Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma. *Sci Rep*. 2017;7:40187.

36. Abudoureyimu M, Zhou H, Zhi Y, et al. Recent progress in the emerging role of exosome in hepatocellular carcinoma. *Cell Prolif*. 2019;52(2):e12541.

37. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. *J Biol Chem*. 1998;273(32):20121-20127.

38. Cheng Z, Lei Z, Yang P, et al. Exosome-transmitted p120-catenin suppresses hepatocellular carcinoma progression via STAT3 pathways. *Mol Carcinog*. 2019;58(8):1389-1399.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Yu S, Chen J, Quan M, Li L, Li Y, Gao Y. CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation. *J Cell Mol Med*. 2021;25:1024–1034. [https://doi.org/10.1111/jcmm.16167](https://doi.org/10.1111/jcmm.16167)